Better Therapeutics, Inc. (NASDAQ:BTTX – Get Rating) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 225,400 shares, a drop of 35.8% from the June 30th total of 351,100 shares. Currently, 2.9% of the company’s stock are sold short. Based on an average trading volume of 6,480,000 shares, the short-interest ratio is presently 0.0 days.
Better Therapeutics Stock Up 11.6 %
Shares of BTTX opened at $2.22 on Friday. The stock’s fifty day moving average price is $1.72 and its two-hundred day moving average price is $2.33. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.86 and a current ratio of 9.86. Better Therapeutics has a 1 year low of $0.91 and a 1 year high of $29.40.
Better Therapeutics (NASDAQ:BTTX – Get Rating) last issued its earnings results on Friday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.11). As a group, equities research analysts anticipate that Better Therapeutics will post -1.99 earnings per share for the current year.
Analyst Upgrades and Downgrades
Insider Buying and Selling at Better Therapeutics
In related news, Director Geoffrey M. Parker bought 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were bought at an average price of $1.45 per share, with a total value of $36,250.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at $58,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders bought 32,281 shares of company stock valued at $48,042. Company insiders own 59.40% of the company’s stock.
Institutional Trading of Better Therapeutics
A hedge fund recently raised its stake in Better Therapeutics stock. Vanguard Group Inc. lifted its stake in shares of Better Therapeutics, Inc. (NASDAQ:BTTX – Get Rating) by 39.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 284,395 shares of the company’s stock after purchasing an additional 80,633 shares during the quarter. Vanguard Group Inc. owned 1.20% of Better Therapeutics worth $563,000 as of its most recent SEC filing. 14.97% of the stock is currently owned by institutional investors.
About Better Therapeutics
Better Therapeutics, Inc engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.
- Get a free copy of the StockNews.com research report on Better Therapeutics (BTTX)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter’s Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.